FDA Accepts Arcutis’ Application for ZORYVE in Infants as Young as 3 Months
Event summary
- FDA accepted Arcutis’ sNDA for ZORYVE cream 0.05% to treat mild-to-moderate atopic dermatitis in infants aged 3–24 months.
- PDUFA target action date set for February 23, 2027.
- Application supported by Phase 2 INTEGUMENT-INFANT and Phase 1 PK studies showing safety, tolerability, and efficacy.
- ZORYVE is already approved for atopic dermatitis in children aged 2–5 years.
- Atopic dermatitis affects ~1 million U.S. infants under age 2.
The big picture
Arcutis is targeting a significant unmet need in pediatric dermatology with ZORYVE, aiming to become the go-to non-steroidal treatment for infants. The FDA’s acceptance of this sNDA reflects both the regulatory gap in approved treatments for very young children and Arcutis’ strategic push to dominate the atopic dermatitis market from infancy through adulthood.
What we're watching
- Regulatory Approval
- Whether the FDA will approve ZORYVE for this expanded indication by the February 2027 PDUFA date.
- Market Expansion
- How Arcutis positions ZORYVE as a foundational treatment across all age groups with atopic dermatitis.
- Competitive Dynamics
- The pace at which competitors develop steroid-free treatments for pediatric atopic dermatitis.